$3.460
-0.144 (-4.16%)At close
MODD News
MODD Events
Modular Medical Plans to Launch Tubeless Patch Pump in Five U.S. Markets in October 2026
Modular Medical announced plans to initiate the first phase of commercialization of its Pivot tubeless patch pump across five strategically selected U.S. markets beginning in October 2026. The initial rollout will include Atlanta, Cincinnati/Lexington, Dallas, Houston, and Philadelphia, representing a foundational step in the Company's capital efficient commercialization strategy with its mission to expand access to simplified insulin delivery solutions for all people living with diabetes.
Modular Medical Forms Pivot Innovation Council
Modular Medical announced the formation of its Pivot Innovation Council. Diabetes care expert Robert Gabbay, MD, PhD, FACP was appointed as chair of the Pivot Innovation Council. The council will provide insights on target patient populations, support optimization of clinical workflows, inform evidence-generation initiatives, and help refine the Pivot product roadmap and go-to-market approach, as the Company continues to scale its differentiated offering.
Modular Medical Partners with IMO Health to Develop Diabetes Algorithm
Modular Medical announced an important pilot collaboration with IMO Health. Through this pilot, Modular Medical and IMO Health expect to develop a deployable terminology-powered phenotypic algorithm designed to identify diabetes patients who may benefit from insulin pump therapy directly within the electronic health record. The pilot aims to help clinicians successfully surface multiple-daily-injection patients, who exhibit clinical characteristics associated with insulin pump hesitancy or prior pump failure, enabling more timely and targeted conversations about modern pump therapy options, such as the Company's Pivot pump.
Modular Medical Releases Positive Market Study Findings for Pivot Tubeless Patch Pump
Modular Medical released findings from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel. As part of its commercialization strategy, the Company partnered with an independent organization specializing in the assessment of market viability, payor access, and commercialization strategies for therapeutic products. The firm specializes in supporting product launches, pricing assessments, reimbursement strategy, and go-to-market planning for life science companies. The objective of the engagement was to better understand payor receptivity, reimbursement considerations, and market positioning opportunities for the Pivot tubeless patch pump.
Modular Medical Submits Software Enhancements for Pivot System to FDA
Modular Medical announced submission to the U.S. Food & Drug Administration of a series of software enhancements to its Pivot insulin delivery system, providing users with more customization options and user-interface improvements, as well as other software upgrades.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.